Table 5.
Intention-to-Treat Analysis of Secondary Outcomes
Outcome | Intervention Group | Control Group | Adjusteda Odds Ratio or Mean Difference (95% CI) | P Value |
---|---|---|---|---|
Drug-specific outcomes | ||||
Proton pump inhibitor, No. (%) | ||||
Baseline | 53 (53.5) | 65 (67.7) | ||
Intervention completion | 23 (23.2) | 46 (47.4) | 0.30 (0.14–0.68) | .04 |
Duplicate, No. (%) | ||||
Baseline | 19 (19.2) | 13 (13.5) | ||
Intervention completion | 11 (11.1) | 11 (11.3) | 0.83 (0.32–2.13) | .99 |
Long-term benzodiazepines, | ||||
No. (%) | ||||
Baseline | 14 (14.1) | 8 (8.1) | ||
Intervention completion | 9 (9.1) | 9 (9.1) | 1.31 (0.47–3.68) | .99 |
Patient-reported outcomes | ||||
WBQ-12 score: mean well-beingb | ||||
Baseline | 24.3 | 24.4 | ||
Intervention completion | 23.6 | 24.0 | –0.41 (−0.80 to 1.07) | .99 |
BMQ score: median necessity-concern differentialc | ||||
Baseline | 7.0 | 5.8 | ||
Intervention completion | 6.0 | 6.0 | 0.16 (−1.85 to 1.07) | .99 |
BMQ = Beliefs About Medicine Questionnaire; WBQ-12 = 12-item Well-Being Questionnaire.
Note: Figures are numbers (percentages) unless stated otherwise. The Bonferroni method was used to account for multiple comparisons.
Adjusted for age, sex, baseline number of PIP drugs, baseline number of repeat medications, number of general practitioners, and practice location.
Well-being score ranges from 0 to 36 (1–12 low, 13–24 medium, 25–36 high).
Scale from −20 to 20, where positive scores indicate benefits outweigh risks.